2016
DOI: 10.1007/s40291-016-0226-z
|View full text |Cite
|
Sign up to set email alerts
|

Genetic Biomarkers to Identify the Risk of Osteonecrosis in Children with Acute Lymphoblastic Leukemia

Abstract: Osteonecrosis is a disabling complication of treatment for pediatric acute lymphoblastic leukemia, and much effort has been made to predict which patients are prone to develop this disease. Multiple clinical and genetic factors have already been identified as being associated with osteonecrosis; however, a prediction model that combines pretreatment genetic biomarkers and clinical factors has not yet been designed. Such a prediction model can only be developed with continuing international collaborations and r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 24 publications
0
1
0
Order By: Relevance
“…Since not all patients exposed to the same treatment will develop ON, we can assume that pathophysiological mechanisms are underpinned by genetic polymorphisms. Some studies go in this direction, with an impact of the nucleotide polymorphisms of the plasminogen activator inhibitor 1-gene, or glutamate receptor GRIN3A 34,35 . The nested case control French GENLEA01 study (Genome-wide association studies GWAS identification of genetic factors affecting the occurrence of late side effects in childhood leukemia survivors from the L.E.A cohort) could help to solve these questions in the future.…”
Section: Discussionmentioning
confidence: 99%
“…Since not all patients exposed to the same treatment will develop ON, we can assume that pathophysiological mechanisms are underpinned by genetic polymorphisms. Some studies go in this direction, with an impact of the nucleotide polymorphisms of the plasminogen activator inhibitor 1-gene, or glutamate receptor GRIN3A 34,35 . The nested case control French GENLEA01 study (Genome-wide association studies GWAS identification of genetic factors affecting the occurrence of late side effects in childhood leukemia survivors from the L.E.A cohort) could help to solve these questions in the future.…”
Section: Discussionmentioning
confidence: 99%